Nagler David 4
4 · Audentes Therapeutics, Inc. · Filed Jun 22, 2018
Insider Transaction Report
Form 4
Nagler David
SVP, HR & Corp. Affairs
Transactions
- Exercise/Conversion
Common Stock
2018-06-20$2.19/sh+4,700$10,270→ 4,700 total - Sale
Common Stock
2018-06-20$46.02/sh−300$13,806→ 0 total - Sale
Common Stock
2018-06-20$45.25/sh−4,700$212,655→ 0 total - Exercise/Conversion
Common Stock
2018-06-20$2.19/sh+300$656→ 300 total - Exercise/Conversion
Stock Option (right to buy)
2018-06-20−5,000→ 32,347 totalExercise: $2.19Exp: 2025-02-04→ Common Stock (5,000 underlying)
Footnotes (4)
- [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $45.00 and the highest price at which shares were sold was $45.97. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- [F3]Represents the weighted average sale price. The lowest price at which shares were sold was $46.00 and the highest price at which shares were sold was $46.06.
- [F4]The option vested as to 25% of the total shares on February 1, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 1, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.